Deflegmin prolonged-release capsules are a mucolytic preparation containing ambroxol hydrochloride.
Always use this medicine exactly as described in the package leaflet or as directed by your doctor or pharmacist. Check with your doctor or pharmacist if you are not sure.
The usual dose of Prolosin prolonged-release capsules:
in adults:
The preparation should not be used immediately before going to bed.
If after 4 to 5 days there is no improvement or the patient feels worse, see a doctor.
- The active substance is ambroxol hydrochloride. One capsule with extended
release contains 75 mg of ambroxol hydrochloride.
- The other ingredients are: sucrose grains, corn starch, shellac, povidone, talc; composition
gelatin capsules: erythrosine (E 127), titanium dioxide (E 171), indigo carmine (E 132), gelatin.
The preparation increases the secretion of mucus in the respiratory tract and improves its transport, thus facilitating expectoration and soothing cough.
Deflegmin is used in acute and chronic lung and bronchial diseases with difficulty expectoration of sticky secretions from the respiratory tract.
If after 4 to 5 days there is no improvement or the patient feels worse, see a doctor.
If you are allergic to ambroxol hydrochloride or any of the other ingredients of this medicine
The preparation should not be used immediately before going to bed.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following side effects, stop taking Prologmin and contact your doctor immediately:
- an allergic reaction with swelling of the face, lips, mouth, tongue and / or throat (angioedema). This can make your throat tight, difficulty swallowing and breathing - the frequency of this side effect is unknown.
- Allergic reactions affecting the whole body (anaphylactic reaction including anaphylactic shock) - the frequency of this side effect is not known.
- severe skin reactions such as Stevens-Johnson syndrome (a severe condition in which the epidermis dies and peels) and toxic epidermal necrolysis (a preparation reaction in which large pieces of the epidermis come apart from deeper layers of the skin); this can also affect the eyes, mouth, throat and bronchi). In their initial phase, nonspecific flu-like symptoms may occur, e.g. fever, pain, rhinitis, cough and sore throat. These side effects are very rare (less than 1 in 10,000 people).
In addition, the following side effects may occur:
Common side effects (may affect up to 1 in 10 people):
- nausea.
Uncommon side effects (may affect up to 1 in 100 people):
- vomiting, diarrhea, indigestion and stomach pain.
Rare side effects (may affect up to 1 in 1,000 people):
- rash, hives.
Not known side effects (frequency cannot be estimated from the available data):
Talk to your doctor or pharmacist before using Deflegmin:
if you have stomach or duodenal ulcers;
- if you have liver or kidney problems;
- if you experience any changes on the skin or mucous membranes, stop taking Deflegmin and contact your doctor immediately;
- if the patient's cough reflex is weakened or there are impaired ciliary clearance of the bronchi (there is a risk of retention of secretions in the respiratory tract);
- if you suffer from bronchial asthma (Deflegmin may make your cough worse at the beginning of treatment).
Tell the doctor or pharmacist about all the preparations taken by the patient now or recently, as well as about the preparations that the patient plans to take.
- Ambroxol increases the concentration of antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) in the lung parenchyma.
- Antitussive preparations (e.g. codeine) inhibit the cough reflex and make it difficult to cough up liquefied mucus, therefore ambroxol should not be used concomitantly with antitussive preparations.
- No significant interaction of ambroxol with other preparations has been demonstrated
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Deflegmin is not recommended during pregnancy, especially in the first trimester of pregnancy.
Ambroxol passes into breast milk. The use of Deflegmin during breastfeeding is not recommended.
The effect of the preparation on human fertility has not been studied.
Animal studies did not show harmful effects of ambroxol on fertility.
Use of the preparation in children and adolescents
The preparation in the form of prolonged-release capsules should not be used in children and adolescents.